BFM
LXRX icon

Boothbay Fund Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Boothbay Fund Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$106K Hold
44,315
– – ﹤0.01% 2042
2026
Q1 		$69.1K Hold
44,315
– – ﹤0.01% 1901
2025
Q4 		$51K Sell
44,315
-11,805
-21% -$16.2K ﹤0.01% 1820
2025
Q3 		$75.8K Hold
56,120
– – ﹤0.01% 1754
2025
Q2 		$53.1K Sell
56,120
-398,771
-88% -$258K ﹤0.01% 1350
2025
Q1 		$210K Sell
454,891
-25,931
-5% -$16.4K 0.01% 1152
2024
Q4 		$355K Buy
+480,822
New +$580K 0.01% 1018
2024
Q1 		– Sell
-14,400
Closed -$22K – 1786
2023
Q4 		$22K Buy
+14,400
New +$17.1K ﹤0.01% 1582

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Boothbay Fund Management's LXRX Position: Q2 2026 in Review

Boothbay Fund Management held its Lexicon Pharmaceuticals (LXRX) position steady in Q2 2026 at 44,315 shares worth $106K. The position accounts for ﹤0.01% of the portfolio, ranked #2042.

Boothbay Fund Management first reported a position in LXRX in Q4 2023 and has held it in 8 quarters since. The position peaked at $355K in Q4 2024. 149 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • Boothbay Fund Management held 44,315 shares of Lexicon Pharmaceuticals worth $106K as of Q2 2026.
  • Boothbay Fund Management left its Lexicon Pharmaceuticals share count unchanged in Q2 2026.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #2042 holding.
  • Boothbay Fund Management first reported a position in Lexicon Pharmaceuticals in Q4 2023 and has held it in 8 quarters since.
  • Boothbay Fund Management's Lexicon Pharmaceuticals position peaked at $355K in Q4 2024.
  • 149 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.